{"name":"RallyBio","slug":"rallybio","ticker":"RLYB","exchange":"NASDAQ","domain":"rallybio.com","description":"Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.","hq":"New Haven, CT","founded":0,"employees":"14","ceo":"Martin Mackay","sector":"Rare Hematology","stockPrice":14.26,"stockChange":-0.09,"stockChangePercent":-0.63,"marketCap":"$75M","metrics":{"revenue":858000,"revenueGrowth":484.2,"grossMargin":0,"rdSpend":19597000,"netIncome":-8978000,"cash":54736000,"dividendYield":0,"peRatio":-2.6,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"RallyBio Announces FDA Clearance for Phase 1 Clinical Trial of RLYB116","summary":"RallyBio received FDA clearance to initiate a phase 1 clinical trial for RLYB116 for Injection, an anti-(integrin beta-3) human monoclonal antibody.","drugName":"RLYB116","sentiment":"positive"},{"date":"2023-08-15","type":"earnings","headline":"RallyBio Reports Second Quarter 2023 Financial Results","summary":"RallyBio reported its second-quarter 2023 financial results, with a net loss of $X.X million.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFAwYnVOdENkaDFnX0NEdjE1aXhqb0ZmZ0NxMmctblpHVjZ6Y3dZaFhKRi1rR2RrdVZPMGVQMjJtWERXZm81NFJ6bmlodTZTb2M5WXVzcmRQMzBtRDJNVktwdnFTaWd0alNTMnlLNEt3?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Rallybio Corp (RLYB) - Stock Titan","headline":"If You Invested $1,000 in Rallybio Corp (RLYB)","sentiment":"neutral"},{"date":"2026-03-16","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQb2NqVFY5RXU4bFZqdDZPcFo3ZURLUHl6QmphaUNlcG5pNGR0ZzlzRk9oZHhHR3hwS3h6TjJrSFpCYVM0NF9jUmloZGdzcEVZSHpyN19lcXFhSjNmQnFWODJURVliUlRRXzhyRmlYZWh4UkVyMzc4bEVwcVF1aWxHMk9EQkp1RFRvNWNtZUVibFFPcEQxaUNTUkE0TGtNZElJcGJDXy0yODM?oc=5","date":"2026-03-04","type":"deal","source":"The Pharma Letter","summary":"Candid lists via Rallybio reverse merger, adds $505m financing - The Pharma Letter","headline":"Candid lists via Rallybio reverse merger, adds $505m financing","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-06","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-08-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQMGctZjlMTkpNclJTckRIYTAwa1FncDBqaUtsVzlaY3hIYjk0ODdCWm9yVW55dHdiUzFjVEg5MTE5TzVCUHFMR0pEM09EemcxNXZvaGsxaW9SQnlMZFoxUDMyeXBDQWx3OFhnQXNvYzJVbGx6ajF6TXh2U1lxY3RGTURDNHVnbnJtXzNkSzZDNURKVWVqTU5r?oc=5","date":"2025-07-20","type":"deal","source":"Yahoo Finance","summary":"Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - Yahoo Finance","headline":"Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-10","type":"pipeline","source":"simplywall.st","summary":"We're Keeping An Eye On Rallybio's (NASDAQ:RLYB) Cash Burn Rate - simplywall.st","headline":"We're Keeping An Eye On Rallybio's (NASDAQ:RLYB) Cash Burn Rate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOT3NkNE9xamVZT0FYZkpNcG0xdjdPbXRRRWJGeTZ6ckkzZmFlZ2QzclJEdjVaRmt1Y0xkOW9NRU8wdmZuc2hMU3l5VThpX29pRFpBaWJ2WkIzUzExdEE2LXQ1T3FMQnN2NnI2RTFaQk9HRFJxbXBlZERiN3BxZ3Q0VDZxckNSMVJ3MnBVUnp3?oc=5","date":"2025-07-09","type":"pipeline","source":"Yahoo Finance","summary":"Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M - Yahoo Finance","headline":"Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOQktlS0RwTVNNUlBxLVN3OU1GZFE1eWVHTktldzkzOUg4M0RHQ283RFU3c1pDUE1OMDE3WGM0REctSlBTYW82SEJEQ01rRWZrMnhDMV9FaUJhaGZUeTBuWnp6Y3BuTUNvLWNtNW1lWkc1aU1PeW40VTNfTU5mYVJpY1lRR3Y?oc=5","date":"2025-07-09","type":"pipeline","source":"Yahoo Finance","summary":"RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program - Yahoo Finance","headline":"RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNeWhNY2ZfWEFFVjNvanBzcXRaRERtNmhiQ0ZUVW51WmxoVDhRVzVzeHFWTmFQNE1BNnZnYUx1LWd3OF9JTzROUkFEanpKNVdDQzlhT0pTZEtGdGNUYnFiNTlfbWpyUjdkT0VpYks4eDY1Rl8zR1dqeExGR2VaVmdnUV9Jam5ZY0toYWw0UjdqNFVUTUxjZjZIeEI3LUJnX21oMzBzTmd4a2pYYUlxSWJSM0p6WE5yamx3Y3I0NVNQakV6dXRNYlE?oc=5","date":"2025-07-08","type":"pipeline","source":"Business Wire","summary":"Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - Business Wire","headline":"Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9iY1RtWXAzRXl6WjdEQ1ZKcER5eVJ5bW9mZlhRSXUtVmwwS2hyZ0lyTkdGMDVRbkw2REF0T3NvUndkUTUwdDZEY3I2VjVLOUtQWU1kNVhXOENDM01zR0VOaDk2a0stbmVRYkp3Yl9VTUhJZ1ZLdG9YelpBY05tNFE?oc=5","date":"2025-07-08","type":"deal","source":"Seeking Alpha","summary":"Rallybio stock climbs on deal with Recursion (RLYB:NASDAQ) - Seeking Alpha","headline":"Rallybio stock climbs on deal with Recursion (RLYB:NASDAQ)","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["BioMarin Pharmaceutical Inc.","Sarepta Therapeutics Inc.","Alexion Pharmaceuticals Inc."],"therapeuticFocus":["Rare Hematology"],"financials":{"source":"sec_edgar+yahoo","revenue":858000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":858000,"period":"2025-12-31"},{"value":600000,"period":"2024-12-31"},{"value":636000,"period":"2024-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":19597000,"rdSpendHistory":[{"period":"2025-12-31","value":19597000},{"period":"2024-12-31","value":41507000},{"period":"2023-12-31","value":53544000},{"period":"2022-12-31","value":40689000}],"sgaSpend":14325000,"operatingIncome":-33064000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-33064000},{"period":"2024-12-31","value":-60496000},{"period":"2023-12-31","value":-78932000},{"period":"2022-12-31","value":-67884000}],"netIncome":-8978000,"netIncomeHistory":[{"period":"2025-12-31","value":-8978000},{"period":"2024-12-31","value":-57775000},{"period":"2023-12-31","value":-74564000},{"period":"2022-12-31","value":-66654000}],"eps":-1.59,"epsHistory":[{"period":"2025-12-31","value":-1.59},{"period":"2024-12-31","value":-10.64},{"period":"2023-12-31","value":-14.72},{"period":"2022-12-31","value":-16.72}],"cash":31374000,"cashHistory":[{"period":"2025-12-31","value":31374000},{"period":"2024-12-31","value":13903000},{"period":"2023-12-31","value":24494000},{"period":"2022-12-31","value":56958000}],"totalAssets":62261000,"totalLiabilities":4305000,"totalDebt":176000,"equity":57956000,"operatingCashflow":-29813000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-29813000},{"period":"2024-12-31","value":-49282000},{"period":"2023-12-31","value":-60265000},{"period":"2022-12-31","value":-57284000}],"capex":-12000,"capexHistory":[{"period":"2023-12-31","value":-12000},{"period":"2022-12-31","value":-54000},{"period":"2021-12-31","value":-333000}],"freeCashflow":-29813000,"dividendsPaid":null,"buybacks":null,"employees":14,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":2979000,"ebit":-6412000,"ebitda":-6409000,"period":"2025-12-31","revenue":222000,"epsBasic":null,"netIncome":-5852000,"rdExpense":3655000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-6412000},{"sga":2994000,"ebit":-6925000,"ebitda":-6890000,"period":"2025-09-30","revenue":212000,"epsBasic":2.88,"netIncome":16016000,"rdExpense":4143000,"epsDiluted":2.88,"grossProfit":null,"operatingIncome":-6925000},{"sga":4195000,"ebit":-10057000,"ebitda":-10031000,"period":"2025-06-30","revenue":212000,"epsBasic":-1.76,"netIncome":-9703000,"rdExpense":6074000,"epsDiluted":-1.76,"grossProfit":null,"operatingIncome":-10057000},{"sga":4157000,"ebit":-9670000,"ebitda":-9642000,"period":"2025-03-31","revenue":212000,"epsBasic":-1.68,"netIncome":-9439000,"rdExpense":5725000,"epsDiluted":-1.68,"grossProfit":null,"operatingIncome":-9670000},{"sga":4261000,"ebit":-11608000,"ebitda":-11578000,"period":"2024-12-31","revenue":38000,"epsBasic":-2,"netIncome":-11044000,"rdExpense":7385000,"epsDiluted":-2,"grossProfit":null,"operatingIncome":-11608000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-2.08,"netIncome":null,"rdExpense":null,"epsDiluted":-2.08,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":14.26,"previousClose":14.35,"fiftyTwoWeekHigh":15.31,"fiftyTwoWeekLow":2.16,"fiftyTwoWeekRange":"2.16 - 15.31","fiftyDayAverage":9.79,"twoHundredDayAverage":6.25,"beta":-1.1,"enterpriseValue":21346836,"forwardPE":-2.6,"priceToBook":1.3,"priceToSales":87.88,"enterpriseToRevenue":24.88,"enterpriseToEbitda":-0.68,"pegRatio":0,"ebitda":-31272000,"ebitdaMargin":0,"freeCashflow":-20342500,"operatingCashflow":-29813000,"totalDebt":176000,"debtToEquity":0.3,"currentRatio":14.51,"returnOnAssets":-30.1,"returnOnEquity":-15,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4.2,"institutionHeldPercent":60.8,"sharesOutstanding":5289675,"floatShares":3150954,"sharesShort":1572902,"shortRatio":23.93,"shortPercentOfFloat":29.7,"epsTrailing":-1.59,"epsForward":-5.4,"revenuePerShare":0.15,"bookValue":10.97,"officers":[{"age":69,"name":"Dr. Martin W. MacKay Ph.D.","title":"Co-Founder & Chairman"},{"age":67,"name":"Dr. Stephen  Uden M.D., MBBS","title":"Co-Founder, President, CEO & Director"},{"age":55,"name":"Mr. Jonathan I. Lieber M.B.A.","title":"CFO & Treasurer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.rallybio.com","phone":"203 859 3820"}}